...
SGMOMICRO

Sangamo Therapeutics, Inc.

HealthcareBiotechnology
$0.43
$0.00(-1.75%)
52W$0.35
$1.06
FinancialsValuationvs ALNY
Updated Mar 2, 12:00 AM
RSI54
RS Rating30/99
Beta1.27
Volatility111%
F-Score1/9
Mkt Cap$92M
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Sangamo Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 30), showing significant lag compared to the market leaders. Earnings contraction of 351% provides fundamental context to the price action. Investors should exercise caution due to high volatility (111% annualized), which requires wider risk management.

Relative Strength
30
out of 99
Lagging
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.27
vs S&P 500
ABOVE MKT
52W Position
12%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$0.42
50 SMA > 100 SMA$0.48
100 SMA > 150 SMA$0.51
150 SMA > 200 SMA$0.50

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$0.41+4.50%ABOVE
50 SMA$0.42+2.95%ABOVE
100 SMA$0.48-9.56%BELOW
150 SMA$0.51-14.41%BELOW
200 SMA$0.50-14.26%BELOW

Price Performance

1D-1.8%
1W+10.4%
1M+20.1%
3M-6.2%
6M-20.1%
YTD-1.8%
1Y-57.6%
3Y-47.9%
52-Week Trading Range12% from low
$0.43
52W Low$0.35
52W High$1.06

Technical Indicators

RSI (14)NEUTRAL
54.1
305070
VCP ScoreCOOL
3/10
Base depth: 57.8%

Risk Profile

Beta
1.27
52W Vol
111%
ATR
$0.04
Max DD (1Y)
-66%

Volume Analysis

Today
—
50D Avg
5.29M
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+68%
$-0.11
Q1'25+48%
$-0.14
Q2'25+57%
$-0.08
Q3'25-351%
$-0.11
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+2.34%
5 Years:-10.81%
3 Years:-19.48%
TTM:-37.13%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+41.33%

Stock Price CAGR

10 Years:-22.08%
5 Years:-48.55%
3 Years:-47.86%
1 Year:-57.62%

Return on Equity

10Y Avg:-59.2%
5Y Avg:-89.2%
3Y Avg:-126.4%
Last Year:-1744.5%

Key Metrics

Market Cap$92M
Gross Margin1.0%
Net Margin-1.7%
Piotroski F-Score1/9

More SGMO Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

SGMO vs ALNYALNYIONSARWRCRSP

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 30 meansSGMO outperformed 30% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.27 means 27% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 1/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 3/10 with COOL status.

Frequently Asked Questions

Is SGMO in an uptrend right now?

SGMO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is SGMO overbought or oversold?

SGMO's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.

Is SGMO outperforming the market?

SGMO has a Relative Strength (RS) Rating of 30 out of 99. SGMO is currently lagging the broader market.

Where is SGMO in its 52-week range?

SGMO is trading at $0.43, which is 41% of its 52-week high ($1.06) and 12% above its 52-week low ($0.35).

How volatile is SGMO?

SGMO has a Beta of 1.27 and 52-week volatility of 111%. It's more volatile than the S&P 500 - expect bigger swings.